将甲氟喹重新定位为抗癌药物：循证综述
Repositioning Mefloquine as an Anticancer Drug: An Evidence-Based Review.
摘要(中文译文)
药物重定位近年来受到广泛关注，尤其是在癌症研究中，因其具有开发创新疗法的潜力。该方法提供了具有成本效益的策略，同时绕过了美国食品药品监督管理局（FDA）施加的一些严格监管障碍。甲氟喹自1960年以来已被广泛研究，并于1989年获得FDA批准用于治疗疟疾。近年来，甲氟喹的抗癌作用被重新发现。大量研究报告的汇总数据表明，甲氟喹在临床前模型中对多种人类恶性肿瘤表现出抗癌活性，包括胃癌和结直肠癌、前列腺癌、宫颈癌、乳腺癌、胶质母细胞瘤和神经母细胞瘤、急性和慢性髓系白血病、食管癌和口腔鳞状细胞癌，在体外和体内研究模型中通过不同的分子机制发挥作用。除诱导凋亡外，研究还表明甲氟喹可通过诱导自噬和铁死亡使癌细胞走向毁灭，使其成为杀伤耐药凋亡癌细胞的有前景的药物。除了作为单药具有抗癌作用外，甲氟喹在联合治疗中已被证明可在多种研究模型中提高临床抗癌药物的疗效。鉴于上述研究发现，甲氟喹可能值得进一步研究其在癌症治疗中的潜在重定位应用，无论是作为单一疗法还是与其它临床实践中的化疗药物联合使用。
Abstract
Drug repurposing has gained significant attention in recent years, particularly in cancer research, due to its potential to develop innovative therapeutics. This approach offers cost-effective strategies while bypassing some of the stringent regulatory hurdles imposed by the Food and Drug Administration (FDA). Mefloquine has been extensively investigated since 1960 and was approved by the FDA in 1989 for the treatment of malaria. Recently, Mefloquine has been rediscovered for its anticancer effects. Collective data from a plethora of research reports show that Mefloquine exhibits anticancer activity in preclinical models against a wide range of human malignancies, including gastric and colorectal cancer, prostate cancer, cervical cancer, breast cancer, glioblastoma and neuroblastoma, acute and chronic myeloid leukemia, esophageal and oral squamous carcinoma through different molecular mechanisms in both in vitro and in vivo study models. In addition to apoptosis, it has been shown to set the cancer cells on the road to ruin via induction of autophagy and ferroptosis, making it a promising drug for killing apoptosis-resistant cancer cells. Apart from its anticancer effects as a single agent, mefloquine has been shown to improve the efficacy of clinical cancer drugs in various study models when used in combination therapy. Keeping in view the aforesaid research findings, Mefloquine may warrant further investigation for potential repurposing in cancer therapy, either as monotherapy or in combination with other clinically practiced chemotherapeutics.
如何引用
AMA
Erum Zafar, Muhammad Faisal Maqbool, Kaleem Maqsood, Muhammad Khan, Humayoun Huma Maqbool, Shahid Bashir. Repositioning Mefloquine as an Anticancer Drug: An Evidence-Based Review.. Current medicinal chemistry. 2026; doi:10.2174/0109298673465091260420202419.
APA
Erum Zafar, Muhammad Faisal Maqbool, Kaleem Maqsood, Muhammad Khan, Humayoun Huma Maqbool, Shahid Bashir (2026). Repositioning Mefloquine as an Anticancer Drug: An Evidence-Based Review.. Current medicinal chemistry. https://doi.org/10.2174/0109298673465091260420202419
GB/T 7714
Erum Zafar, Muhammad Faisal Maqbool, Kaleem Maqsood, Muhammad Khan, Humayoun Huma Maqbool, Shahid Bashir. Repositioning Mefloquine as an Anticancer Drug: An Evidence-Based Review.[J]. Current medicinal chemistry, 2026 doi:10.2174/0109298673465091260420202419.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出